Surgical Strategy for Papillary Thyroid Microcarcinoma|RISS 상세보기

다국어 초록 (Multilingual Abstract)

It is generally agreed that papillary thyroid microcarcinoma (PTMC) demonstrates indolent biological behavior.
But PTMCs include at least two biologically distinct subpopulations: indolent tumors with minimal or no potential for progression, and tumors with the propensity for aggressive behavior and dissemination. The ability to stratify those relatively few patients with aggressive PTMC from the vast majority who are low-risk is crucial to offer most appropriate clinical management. Risk factors such as tumor size, age, sex, tumor multifocality, vascular or capsular invasion, extrathyroidal extension, lymph node metastases, histological variants of papillary thyroid cancer (PTC), the presence of mutational markers, and incidentalness need to be considered for a risk-adapted algorithmic approach that would hope to achieve minimal morbidity while still anticipating optimal outcomes at less cost to the patient and to society. But risk factors for recurrence have not been confirmed because of such low recurrence rates, rare mortality rate, and several selection (or therapeutic) biases present in any retrospective series. Larger scale cohort studies showed that recurrence rates did not differ statistically between patients treated with unilateral lobectomy and those treated with bilateral resection, so long as complete tumor resection was achieved. Similarly, more aggressive nodal dissection failed to yield the anticipated reduction in recurrence rates. In conclusion, selection of the minority of PTMC who deserves more aggressive surgery is important, reserving less aggressive treatments for the other, the large majority cases. The ability to stratify those relatively few patients with aggressive PTMC from the vast majority who are low-risk is crucial to offer most appropriate surgical strategy.

번역하기

참고문헌 (Reference)

1 McDougall IR, "Treatment of micropapillary carcinoma of the thyroid: where do we draw the line?" 17 (17): 1093-1096, 2007

2 Roti E, "Thyroid papillary microcarcinoma: a descriptive and metaanalysis study" 159 (159): 659-673, 2008

3 Sacco R, "Thyroid microcarcinoma and multinodular struma. Personal experience and considerations regarding surgical therapy" 58 (58): 69-75, 2006

4 Yamashita H, "Thyroid carcinoma in benign thyroid diseases. An analysis from minute carcinoma" 35 (35): 781-788, 1985

5 Chigot JP, "Thyroid cancer in patients with hyperthyroidism" 29 (29): 1969-1972, 2000

6 Yamashita H, "Thyroid cancer associated with adenomatous goiter: an analysis of the incidence and clinical factors" 27 (27): 495-499, 1997

7 Bisi H, "The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma" 64 (64): 1888-1893, 1989

8 McCoy KL, "The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size" 142 (142): 837-844, 2007

9 Lin KL, "The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma" 17 (17): 3294-3300, 2010

10 Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma" 63 (63): 588-593, 2005